Amyotrophic lateral sclerosis (ALS), also called Lou Gehrig's disease, is the most common of the five motor neuron diseases characterized by progressive neurodegeneration of motor neurons in the brain stem and spinal cord. Currently, there is no cure or effective treatment for ALS. The cause of disease is unknown in the majority of ALS cases. Less than 10% of ALS cases are familial, involving mutations in several genes such as SOD1 and TARDBP. The protein encoded by TARDBP, i.e. TAR DNA-binding protein 43 (TDP-43), was identified as a major component of the histopathological hallmark, i.e., neuronal ubiquitinated inclusions, of degenerating neurons in most forms of ALS and increasing evidence suggests a critical role of TDP-43 in diverse neurodegenerative diseases including ALS and frontotemporal lobar degeneration (FTLD). Unfortunately, how TDP-43 mutant causes neurodegeneration is poorly understood. Interestingly, in our preliminary studies, we also observed significant impairment of mitochondrial bioenergetics in motor neuronal cell lines expressing mutant TDP-43. As mitochondrial dysfunction plays a prominent role in ALS, further more detailed studies should be performed to assess the effect of mutant TDP-43 on mitochondrial function in primary motor neurons in vitro and in vivo, and explore potential underlying mechanisms by which mutant TDP- 43 cause mitochondrial dysfunction. TDP-43 translocates from the nucleus to cytoplasm in of ALS and frontotemporal lobar degeneration (FTLD-U). Unfortunately, few attempt has been taken to investigate its subcellular organelle target(s). Excitingly, our pilot studies found that TDP-43 could be present in the matrix of mitochondria. And, more importantly, TDP-43 interacts with a matrix facing protein critical for mitochondrial electron transport chain, and binds mitochondrial genome encoded mRNA, indicating a direct role of TDP-43 in regulating mitochondrial function. All these exciting finding strongly suggest that TDP-43 may impair mitochondrial function through its specific localization in mitochondria which adversely affects neuronal functions in ALS. Thus, it is important to investigate how TDP-43 is taken up by mitochondria and test whether TDP-43 mitochondrial localization is required for its toxicity on mitochondria and neurons. Our proposed study will be the first systematic and mechanistic study of TDP-43 mitochondrial import as well as TDP-43 induced mitochondrial dysfunction. Our proposed studies will reveal a novel role of TDP-43 in the regulation of mitochondrial function and likely provide novel therapeutic targets for ALS.

Public Health Relevance

Mutations in TDP-43 gene cause both familial and sporadic amyotrophic lateral sclerosis (ALS) and TDP-43 pathology is a pathological hallmark of ALS. Although mitochondrial dysfunction is an early and prominent feature in ALS, it is still unclear about the mechanism underlying mitochondrial dysfunction and neurodegeneration in the disease. Our group, for the first time, found the presence of TDP-43 in mitochondria. We propose to perform the detailed investigation of how wild type and mutant TDP-43 are taken up by mitochondria and explore whether and how wild type and mutant TDP-43 in mitochondria is involved in the regulation of mitochondrial and neuronal function. The completion of this project will provide new insights about the pathogenesis of ALS and may lead to novel therapeutic targets for ALS.

Agency
National Institute of Health (NIH)
Institute
National Institute of Neurological Disorders and Stroke (NINDS)
Type
Research Project (R01)
Project #
1R01NS089604-01
Application #
8799706
Study Section
Neural Oxidative Metabolism and Death Study Section (NOMD)
Program Officer
Gubitz, Amelie
Project Start
2014-09-30
Project End
2019-07-31
Budget Start
2014-09-30
Budget End
2015-07-31
Support Year
1
Fiscal Year
2014
Total Cost
$346,719
Indirect Cost
$127,969
Name
Case Western Reserve University
Department
Pathology
Type
Schools of Medicine
DUNS #
077758407
City
Cleveland
State
OH
Country
United States
Zip Code
44106
Gao, Ju; Wang, Luwen; Huntley, Mikayla L et al. (2018) Pathomechanisms of TDP-43 in neurodegeneration. J Neurochem :
Wang, Luwen; Gao, Ju; Liu, Jingyi et al. (2018) Mitofusin 2 Regulates Axonal Transport of Calpastatin to Prevent Neuromuscular Synaptic Elimination in Skeletal Muscles. Cell Metab 28:400-414.e8
Yan, Tingxiang; Wang, Luwen; Gao, Ju et al. (2018) Rab10 Phosphorylation is a Prominent Pathological Feature in Alzheimer's Disease. J Alzheimers Dis 63:157-165
Wang, Wenzhang; Arakawa, Hiroyuki; Wang, Luwen et al. (2017) Motor-Coordinative and Cognitive Dysfunction Caused by Mutant TDP-43 Could Be Reversed by Inhibiting Its Mitochondrial Localization. Mol Ther 25:127-139
Wang, Xiaowan; Zhang, Qiao; Bao, Ruisi et al. (2017) Deletion of Nampt in Projection Neurons of Adult Mice Leads to Motor Dysfunction, Neurodegeneration, and Death. Cell Rep 20:2184-2200
Wang, Wenzhang; Wang, Luwen; Lu, Junjie et al. (2016) The inhibition of TDP-43 mitochondrial localization blocks its neuronal toxicity. Nat Med 22:869-78
Wang, Wenzhang; Wang, Xinglong; Fujioka, Hisashi et al. (2016) Parkinson's disease-associated mutant VPS35 causes mitochondrial dysfunction by recycling DLP1 complexes. Nat Med 22:54-63
Wang, Wenzhang; Zhang, Fan; Li, Li et al. (2015) MFN2 couples glutamate excitotoxicity and mitochondrial dysfunction in motor neurons. J Biol Chem 290:168-82
Jiang, Zhen; Wang, Wenzhang; Perry, George et al. (2015) Mitochondrial dynamic abnormalities in amyotrophic lateral sclerosis. Transl Neurodegener 4:14
Zhang, Fan; Wang, Wenzhang; Siedlak, Sandra L et al. (2015) Miro1 deficiency in amyotrophic lateral sclerosis. Front Aging Neurosci 7:100